Holen Sie sich die Stockscreener-App
14.46
0.24%
-0.06
Schlusskurs vom Vortag:
$14.52
Offen:
$14.64
24-Stunden-Volumen:
177.95K
Relative Volume:
0.08
Marktkapitalisierung:
$4.55B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-21.25
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+2.08%
1M Leistung:
+11.77%
6M Leistung:
+69.61%
1J Leistung:
+84.52%
1-Tages-Spanne:
$14.33
$14.69
1-Wochen-Bereich:
$14.00
$14.98
52-Wochen-Spanne:
$6.685
$15.00
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs ZTS, TAK, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
14.48 | 4.56B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
127.69 | 56.15B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 56.52B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
HLN
Haleon Plc Adr
|
10.87 | 48.90B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.41 | 39.90B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
476.25 | 20.90B | 3.13B | 1.27B | 1.12B | 26.39 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-06 | Eingeleitet | Goldman | Buy |
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Breakouts Watch: What’s the outlook for SPAR Group Inc.’s sectorTrade Analysis Summary & High Win Rate Trade Alerts - baoquankhu1.vn
Is Amneal Pharmaceuticals (AMRX) a Great Value Stock Right Now? - Yahoo Finance
Guidance Update: Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdTrade Analysis Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Amneal Pharmaceuticals Refinances Term Loans, Lowers Interest Costs - TipRanks
Amneal Pharma Says On Feb 2nd, Co Enters Amendment No. 2 To Term Loan Credit AgreementSEC Filing - TradingView
Amneal Pharmaceuticals Signs Term Loan Credit Agreement Amendment With JPMorgan Chase - TradingView
How Investors Are Reacting To Amneal Pharmaceuticals (AMRX) Index Additions And Opioid Settlement Resolution - Sahm
Will Amneal (AMRX) beat estimates again in its next earnings report? - MSN
Aug Sentiment: Is Amneal Pharmaceuticals Inc stock a hidden gem2025 Pullback Review & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Risk Check: Does Ormat Technologies Inc stock benefit from AI growth2025 Market Outlook & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
AustralianSuper Pty Ltd Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run? - Yahoo Finance
Amneal initiates nationwide settlement for opioid-related claims - MSN
Opioid Settlement And Index Inclusion Reframe Amneal Pharmaceuticals Risk And Reach - Yahoo Finance
If You Invested $100 In Amneal Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Sahm
Published on: 2026-01-30 06:37:48 - baoquankhu1.vn
Amneal initiates nationwide opioid settlement (AMRX:NASDAQ) - Seeking Alpha
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi Year Run? - Sahm
Amneal Finalizes Nationwide Opioid Settlement Implementation Plan - TipRanks
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index - The Manila Times
Amneal Pharma To Settle Majority Of Opioids-Related Claims - TradingView
Amneal Pharmaceuticals Finalizes Nationwide Opioids Settlement - TradingView
Amneal Pharmaceuticals, Inc. Added to S&P SmallCap 600® Index - Quiver Quantitative
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Amneal Pharmaceuticals (NASDAQ:AMRX) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by SG Americas Securities LLC - MarketBeat
TTM Technologies, Dutch Bros to join S&P 400 Index; Amneal, Apellis to be part of S&P SmallCap 600 (CIVI:NYSE) - Seeking Alpha
Amneal, LegalZoom, others rise as S&P Dow Jones Indices announces index changes - Investing.com Canada
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600 - Benzinga
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026 - The Manila Times
Can Amneal Pharmaceuticals Inc. be the next market leaderWeekly Stock Report & Safe Entry Momentum Tips - mfd.ru
Risk Recap: Can Amneal Pharmaceuticals Inc. be the next market leaderNew Guidance & High Accuracy Swing Entry Alerts - baoquankhu1.vn
2 Reasons to Sell AMRX and 1 Stock to Buy Instead - Finviz
Can Amneal Pharmaceuticals Inc. continue delivering strong returnsJuly 2025 Volume & AI Enhanced Trading Alerts - mfd.ru
Stock Recap: Is ACAD in a bullish channelJuly 2025 Short Interest & Smart Allocation Stock Reports - baoquankhu1.vn
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum - Sahm
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Profit Recap: Is Amneal Pharmaceuticals Inc in a long term uptrend2025 Geopolitical Influence & Advanced Technical Signal Analysis - baoquankhu1.vn
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighHere's Why - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.48 - Investing.com
Gains Recap: Is Amneal Pharmaceuticals Inc stock undervalued right nowCEO Change & Community Consensus Picks - baoquankhu1.vn
Geopolitics Watch: Should I buy KNTK stock nowWeekly Stock Analysis & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth - simplywall.st
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Increase in Short Interest - MarketBeat
Portfolio Recap: Can Amneal Pharmaceuticals Inc be the next market leader2025 Analyst Calls & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Amneal unveils new brand identity to reimagine access to medicine - MediaNews4U
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock? - sharewise.com
Trade Recap: Is Amneal Pharmaceuticals Inc a potential multi baggerPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):